Practical Pharmacokinetic-Pharmacodynamic Models in Oncology

Area of Science:

• Pharmacology and Oncology
• Mathematical Modeling

Background:

• Integrated pharmacokinetic (PK) and pharmacodynamic (PD) models are crucial for understanding drug exposure-response relationships.
• These models guide optimal dosing in drug development and clinical practice, particularly in oncology.

Purpose of the Study:

• To summarize established PK-PD models in oncology, focusing on combination therapies.
• To highlight advancements in PK-PD modeling for predicting drug interactions and efficacy in complex treatment regimens.

Main Methods:

• Review of PK models including non-compartmental, compartmental, and physiologically based approaches.
• Integration of disease progression models (e.g., logistic growth, Gompertzian) with PD models (e.g., indirect response, tumor growth inhibition).
• Development and application of novel PK-PD models for combination therapy, incorporating interaction factors and algorithms like the Combination Index method.

Main Results:

• PK-PD models effectively recapitulate and predict antitumor drug efficacy for monotherapies and combination therapies.
• Established models describe chemotherapy, targeted therapy, and immunotherapy exposure.
• A new PK-PD model for combination therapy addresses limitations of single interaction parameters, improving prediction of synergism, additivity, or antagonism.

Conclusions:

• PK-PD modeling is essential for optimizing anticancer drug combinations.
• Further optimization of these models is needed to advance understanding and develop improved therapies.
• Advanced PK-PD models facilitate critical definition of combination effects and personalized treatment strategies.